A Phase I/II Open-Label Extension of Study TIGEM1-MPSVI, Evaluating the Safety and Efficacy of FT005, an Adeno-Associated Viral Vector 8 to Deliver the Human ARSB Gene to the Liver of Subjects with Mucopolysaccharidosis type VI (MPS VI)
Mucopolysaccharidosis type VI (MPS VI) is a rare genetic condition. People with MPS VI do not produce enough of an enzyme called ARSB. Without this enzyme, complex sugars build up in organs and tissues, leading to joint stiffness, bone issues, heart problems, and breathing difficulties. This clinical trial is testing an experimental gene therapy called FT005. It uses a harmless, modified virus to deliver a working copy of the ARSB gene straight to liver cells. The goal is to allow the liver to create the missing enzyme on its own and clear out excess sugars. Participants also take steroid medicines to keep their immune system calm so the treatment can work safely. Because this is an extension study, researchers are following participants over a longer period. They will closely track side effects, walking endurance, heart and lung function, and sugar levels in the urine to measure success.
एक नजर में
यह अध्ययन किस बारे में है?
MPS VI (Mucopolysaccharidosis type VI) is an inherited condition caused by a faulty gene. Normally, the body uses an enzyme called ARSB to break down complex sugars known as GAGs. In people with MPS VI, this enzyme is missing or does not work properly. As a result, GAGs gradually build up in tissues and organs across the body. Over time, this build-up can cause problems with movement, bone growth, vision, the heart, and the lungs.
Traditional treatments often rely on weekly enzyme infusions through a drip, which can be time-consuming and only manage symptoms temporarily. FT005 is a gene therapy designed to offer a longer-lasting solution. It uses a harmless, deactivated virus (an AAV vector) to carry a healthy ARSB gene directly into liver cells. Once delivered, the liver can act like an internal factory, producing the missing ARSB enzyme and sending it into the bloodstream.
This particular trial is an 'extension study', meaning it builds on an earlier trial (TIGEM1-MPSVI) to monitor patients over a longer timeframe. The main goals are to confirm that the therapy is safe, see whether it causes any unwanted reactions, and check if it keeps sugar levels in the urine low. Doctors will also measure whether the treatment helps participants walk further, breathe easier, and enjoy a better day-to-day quality of life.
If FT005 proves both safe and effective, it could offer a major step forward for MPS VI care. A single gene therapy treatment could potentially reduce or replace the need for frequent hospital infusions, helping to protect organs from long-term damage.
मुख्य निष्कर्ष
- Tests an experimental gene therapy (FT005) for MPS VI.
- Aims to help liver cells produce the missing ARSB enzyme.
- Open to patients of any age who meet the specific trial criteria.
- Uses steroid medication to help the body safely accept the new gene.
- Involves ongoing clinic visits for heart, lung, eye, and walking checks.
- Participation is entirely voluntary, and you can leave the study at any time.
कौन पात्र हो सकता है?
This study is open to both male and female patients with MPS VI. The study does not set strict upper or lower age limits, meaning both children and adults may be considered.
Because this is an 'open-label extension' study, it is generally intended for individuals who were already enrolled in the initial TIGEM1-MPSVI trial. Participants must be able to attend regular hospital check-ups and undergo routine monitoring, such as blood and urine tests.
Participants also need to be able to safely take steroid medicines (such as prednisone). These medicines temporarily quiet the immune system so that it does not attack the harmless virus used to deliver the new gene. Your trial doctor will carefully review your medical history to make sure taking part is safe for you or your child.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- Have a confirmed medical diagnosis of MPS VI.
- Previously took part in the initial TIGEM1-MPSVI study (or invited by the trial team).
- Able to safely take steroid medicines like prednisone.
- Able to attend regular hospital check-ups and follow-up visits.
- Willing to complete physical tests like walking and breathing assessments.
भागीदारी में क्या शामिल है?
Taking part involves receiving a single infusion of the FT005 gene therapy into a vein, alongside courses of steroid medicines (prednisone or methylprednisolone) taken as tablets or injections to prevent inflammation. After the treatment, you will attend regular hospital appointments over several years so the research team can monitor your health. These visits will involve standard checks such as urine tests (to measure sugar levels), blood tests, heart checks (ECGs and ultrasound scans), eye exams, and lung breathing tests. You will also be asked to do simple movement tasks, like a six-minute walk or three-minute stair climb, and complete questionnaires about your daily life.
संभावित जोखिम और लाभ
स्थान (1)
- —असत्यापितइटली
सामान्य प्रश्न
What is MPS VI?
MPS VI is a rare genetic condition where the body cannot make an enzyme needed to break down natural sugars, causing them to build up and damage organs.
How does this gene therapy work?
FT005 uses a harmless, modified virus to carry a healthy copy of the missing gene into liver cells, allowing the liver to produce the missing enzyme.
Why do participants need to take steroids?
Steroid medicines temporarily calm the immune system so it does not attack the viral carrier, helping the gene therapy reach the liver safely.
Will taking part cure MPS VI?
This trial is testing whether the therapy is safe and effective. While doctors hope it will provide long-term improvement, it is too early to call it a cure.
Does taking part cost anything?
No. The study treatment and all trial-related tests are provided free of charge, and travel expenses for hospital visits are usually covered.
और अधिक जानने के लिए कैसे पता करें
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.